JBIO
Jade Biosciences, Inc.
Price Chart
Latest Quote
$21.81
-0.09 (-0.41%)
Current Price
| Previous Close | $21.90 |
| Open | $22.00 |
| Day High | $22.98 |
| Day Low | $21.53 |
| Volume | 813,713 |
Stock Information
| Shares Outstanding | 60.86M |
| Total Debt | $849K |
| Cash Equivalents | $311.30M |
| Net Income | $-95.10M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.33B |
| EPS (TTM) | $-2.63 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $766.09M |
| Income | $-95.10M |
| Book/sh | $6.01 |
| Cash/sh | $5.11 |
| Employees | 55 |
Financial Ratios
| Quick Ratio | 13.96 |
| Current Ratio | 14.29 |
| Debt/Eq | 0.29 |
Returns & Margins
Ownership
| Insider Ownership | 0.93% |
| Institutional Ownership | 84.82% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.57 |
| P/B | 3.63 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $48.50 |
Technical Indicators
| SMA20 | $17.89 |
| SMA50 | $21.44 |
| SMA200 | $14.93 |
| RSI | 66.11 |
| ATR | 1.6960 |
| Shares Float | 39.69M |
| Short Float | 8.38% |
| Short Ratio | 5.79 |
| Rel Volume | 0.51 |
Performance History
| Week | +29.28% |
| Month | +0.46% |
| Quarter | +56.34% |
| 6 Months | +29.28% |
| YTD | +54.03% |
| Year | +108.11% |
| 3 Years | -96.10% |
| 10 Years | -97.20% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $21.81 | 816,001 |
| 2026-06-24 | $21.90 | 1,397,100 |
| 2026-06-23 | $21.97 | 1,410,100 |
| 2026-06-22 | $19.45 | 1,869,800 |
| 2026-06-18 | $16.82 | 4,785,300 |
| 2026-06-17 | $16.87 | 738,100 |
| 2026-06-16 | $15.53 | 1,324,300 |
| 2026-06-15 | $16.10 | 1,295,800 |
| 2026-06-12 | $15.34 | 1,046,600 |
| 2026-06-11 | $16.08 | 806,400 |
| 2026-06-10 | $15.26 | 1,375,100 |
| 2026-06-09 | $15.22 | 1,598,200 |
| 2026-06-08 | $14.98 | 1,466,300 |
| 2026-06-05 | $16.94 | 2,600,900 |
| 2026-06-04 | $17.74 | 3,509,100 |
| 2026-06-03 | $17.59 | 558,300 |
| 2026-06-02 | $17.75 | 993,300 |
| 2026-06-01 | $18.59 | 2,689,100 |
| 2026-05-29 | $21.04 | 1,125,900 |
| 2026-05-28 | $20.84 | 528,200 |
| 2026-05-27 | $21.50 | 385,500 |
| 2026-05-26 | $21.71 | 606,400 |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
đ° Latest News
Jade Biosciencesâ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
MarketBeat âĸ 2026-06-02T01:07:58ZAssessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term Gains
Simply Wall St. âĸ 2026-05-29T01:03:44Z
Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In Growth
Simply Wall St. âĸ 2026-03-28T12:14:17Z
Jade Biosciences Touts âBest-in-Classâ Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
MarketBeat âĸ 2026-02-28T16:41:34Z
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
Insider Monkey âĸ 2026-01-19T13:01:49Z
Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week
Simply Wall St. âĸ 2026-01-06T12:07:13Z
Jade Biosciences (JBIO): Analyst Lauds Entry into Market
Insider Monkey âĸ 2025-12-10T19:15:52Z
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?
Zacks âĸ 2025-12-04T14:55:02Z
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock
Zacks âĸ 2025-11-18T17:00:04Z
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know
Zacks âĸ 2025-11-18T14:55:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Revenue | |
| Total Revenue | $0 |
| Operating Revenue | $0 |
| Expenses | |
| Total Expenses | $113,542,000 |
| Other Income Expense | $-21,592,000 |
| Other Non Operating Income Expenses | $-21,592,000 |
| Net Non Operating Interest Income Expense | $7,782,000 |
| Operating Expense | $113,542,000 |
| General And Administrative Expense | $20,421,000 |
| Income & Earnings | |
| Net Income From Continuing Operation Net Minority Interest | $-127,410,000 |
| Net Interest Income | $7,782,000 |
| Interest Income | $7,782,000 |
| Normalized Income | $-127,410,000 |
| Net Income From Continuing And Discontinued Operation | $-127,410,000 |
| Total Operating Income As Reported | $-113,542,000 |
| Net Income Common Stockholders | $-127,410,000 |
| Net Income | $-127,410,000 |
| Net Income Including Noncontrolling Interests | $-127,410,000 |
| Net Income Continuous Operations | $-127,410,000 |
| Pretax Income | $-127,352,000 |
| Interest Income Non Operating | $7,782,000 |
| Operating Income | $-113,542,000 |
| Per Share | |
| Diluted EPS | $-3.19 |
| Basic EPS | $-3.19 |
| Other | |
| Tax Effect Of Unusual Items | $0 |
| Tax Rate For Calcs | $0 |
| Normalized EBITDA (Bullshit earnings) | $-113,516,000 |
| Reconciled Depreciation | $26,000 |
| EBITDA (Bullshit earnings) | $-113,516,000 |
| EBIT | $-113,542,000 |
| Diluted Average Shares | $31,359,958 |
| Basic Average Shares | $31,359,958 |
| Diluted NI Availto Com Stockholders | $-127,410,000 |
| Tax Provision | $58,000 |
| Research And Development | $93,121,000 |
| Selling General And Administration | $20,421,000 |
| Other Gand A | $7,730,000 |
| Salaries And Wages | $12,691,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $332,518,000 | $-46,799,000 |
| Total Assets | $349,781,000 | $72,799,000 |
| Total Non Current Assets | $965,000 | $3,145,000 |
| Other Non Current Assets | $69,000 | $3,145,000 |
| Current Assets | $348,816,000 | $69,654,000 |
| Other Current Assets | $12,658,000 | $268,000 |
| Cash Cash Equivalents And Short Term Investments | $336,158,000 | $69,386,000 |
| Cash And Cash Equivalents | $88,438,000 | $69,386,000 |
| Debt | ||
| Total Debt | $724,000 | $107,600,000 |
| Long Term Debt And Capital Lease Obligation | $724,000 | $107,600,000 |
| Net Debt | - | $38,214,000 |
| Long Term Debt | - | $107,600,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $17,263,000 | $119,598,000 |
| Total Non Current Liabilities Net Minority Interest | $724,000 | $107,602,000 |
| Current Liabilities | $16,539,000 | $11,996,000 |
| Payables And Accrued Expenses | $13,216,000 | $8,128,000 |
| Payables | $2,151,000 | $1,290,000 |
| Accounts Payable | $2,151,000 | $1,290,000 |
| Other Current Liabilities | - | $1,077,000 |
| Equity | ||
| Common Stock Equity | $332,516,000 | $-46,799,000 |
| Preferred Stock Equity | $2,000 | - |
| Total Equity Gross Minority Interest | $332,518,000 | $-46,799,000 |
| Stockholders Equity | $332,518,000 | $-46,799,000 |
| Gains Losses Not Affecting Retained Earnings | $129,000 | $0 |
| Other Equity Adjustments | $129,000 | - |
| Retained Earnings | $-174,389,000 | $-46,979,000 |
| Preferred Securities Outside Stock Equity | $0 | $2,000 |
| Other | ||
| Ordinary Shares Number | $49,316,287 | $32,235,926 |
| Share Issued | $49,316,287 | $32,235,926 |
| Tangible Book Value | $332,516,000 | $-46,799,000 |
| Invested Capital | $332,516,000 | $60,801,000 |
| Working Capital | $332,277,000 | $57,658,000 |
| Capital Lease Obligations | $724,000 | $0 |
| Total Capitalization | $332,518,000 | $60,801,000 |
| Additional Paid In Capital | $506,771,000 | $179,000 |
| Capital Stock | $7,000 | $1,000 |
| Common Stock | $5,000 | $1,000 |
| Preferred Stock | $2,000 | $0 |
| Long Term Capital Lease Obligation | $724,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,323,000 | $2,791,000 |
| Current Accrued Expenses | $11,065,000 | $6,838,000 |
| Net PPE | $896,000 | $0 |
| Gross PPE | $896,000 | $0 |
| Other Properties | $896,000 | - |
| Other Short Term Investments | $247,720,000 | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-94,885,000 |
| Operating Activities | |
| Operating Cash Flow | $-94,689,000 |
| Cash Flow From Continuing Operating Activities | $-94,689,000 |
| Investing Activities | |
| Capital Expenditure | $-196,000 |
| Investing Cash Flow | $-247,006,000 |
| Cash Flow From Continuing Investing Activities | $-247,006,000 |
| Net Other Investing Changes | $-31,000 |
| Financing Activities | |
| Issuance Of Capital Stock | $189,111,000 |
| Financing Cash Flow | $360,768,000 |
| Cash Flow From Continuing Financing Activities | $360,768,000 |
| Net Other Financing Charges | $171,273,000 |
| Net Common Stock Issuance | $189,111,000 |
| Common Stock Issuance | $189,111,000 |
| Other | |
| Issuance Of Debt | $0 |
| End Cash Position | $88,438,000 |
| Beginning Cash Position | $69,386,000 |
| Effect Of Exchange Rate Changes | $-21,000 |
| Changes In Cash | $19,073,000 |
| Proceeds From Stock Option Exercised | $384,000 |
| Net Issuance Payments Of Debt | $0 |
| Net Long Term Debt Issuance | $0 |
| Long Term Debt Issuance | $0 |
| Net Investment Purchase And Sale | $-246,779,000 |
| Sale Of Investment | $14,415,000 |
| Purchase Of Investment | $-261,194,000 |
| Net PPE Purchase And Sale | $-196,000 |
| Purchase Of PPE | $-196,000 |
| Change In Working Capital | $-8,197,000 |
| Change In Other Current Liabilities | $40,000 |
| Change In Other Current Assets | $-38,000 |
| Change In Payables And Accrued Expense | $3,770,000 |
| Change In Accrued Expense | $3,409,000 |
| Change In Payable | $361,000 |
| Change In Account Payable | $361,000 |
| Change In Prepaid Assets | $-11,969,000 |
| Other Non Cash Items | $21,667,000 |
| Stock Based Compensation | $20,009,000 |
| Amortization Of Securities | $-784,000 |
| Depreciation Amortization Depletion | $26,000 |
| Depreciation And Amortization | $26,000 |
| Depreciation | $26,000 |
| Net Income From Continuing Operations | $-127,410,000 |
Fetched: 2026-06-17